entertainment -WSS

entertainment

author：entertainment 2025-09-06 03:54:31 - browse：78

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： After Sarepta trial failure, Duchenne families brace for more debate

focus

WSS

Key Senate panel to consider PBM, drug pricing reform package

Readout LOUD podcast: ESMO highlights & Roivant's big deal

MoonLake credibility takes another hit with mid

Explaining an after

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Free speech concerns arise in wake of journal editor Eisen's firing

hotspot

entertainment

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Life sciences investors close nearly $6 billion in new funds

Dobbs anniversary: the lost opportunity of abortion as health care

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Malaria cases in Florida and Texas: Here’s what you need to know

Prime Medicine says its gene editing passes test in monkeys

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Virginia high school admissions case could be legal follow

Live blog: Hearing on CRISPR

knowledge

Live blog: Hearing on CRISPR

The health care issue Democrats can’t solve: hospital reform

Senate panel clears PBM, hopsital reforms

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Coloradans with cystic fibrosis could lose access to Trikafta

FDA approves Recor Medical high blood pressure device

knowledge

focus

explore

Wikipedia